Use of COVID-19 Vaccines in the United States

Interim Clinical Considerations

Summary of recent changes (last updated March 16, 2023):
  • New recommendation for children ages 6 months–4 years who previously completed a 3-dose monovalent Pfizer-BioNTech primary series to receive 1 bivalent Pfizer-BioNTech booster dose at least 2 months after completion of the monovalent primary series.
  • Vaccination providers are now required to report cases of myocarditis and pericarditis after receipt of a Janssen COVID-19 Vaccine to the Vaccine Adverse Event Reporting System (VAERS).